Search
Filters

Commercialized//Validated

Under validation

Under development

PDF

Download Product list

clear all filters

Name

Structure

CAS No.

Quality Standard
Application
status
Apalutamide
956104-40-8
In house
Prostate cancer
Commercialized//Validated
Apixaban
503612-47-3
In house
Anticoagulant
Commercialized//Validated
Avatrombopag maleate
570406-98-3
In house
Antithrombocytopenics
Commercialized//Validated
Azilsartan
147403-03-0
In house
Antihypertensive
Commercialized//Validated
Azilsartan medoxomil potassium
863031-24-7
In house
Antihypertensive
Commercialized//Validated
Brexpiprazole
913611-97-9
In house
Antidepressants
Commercialized//Validated
Brivaracetam
357336-20-0
In house
Antiepileptic
Commercialized//Validated
Cabozantinib malate
1140909-48-3
In house
Anticancer
Commercialized//Validated
Canagliflozin hemihydrate
928672-86-0
In house
SGL2 Inhibitor/Antidiabetic
Commercialized//Validated
Candesartan cilexetil
145040-37-5
USP/EP
Antihypertensive
Commercialized//Validated
Dabigatran etexilate mesylate
872728-81-9
In house
Anticoagulant
Commercialized//Validated
Dapagliflozin
960404-48-2
In house
SGL2 Inhibitor/Antidiabetic
Commercialized//Validated
Edoxaban tosylate monohydrate
1229194-11-9
In house
Anticoagulant
Commercialized//Validated
Elagolix sodium
832720-36-2
In house
Pain due to endometriosis
Commercialized//Validated
Empagliflozin
864070-44-0
In house
SGL2 Inhibitor/Antidiabetic
Commercialized//Validated
Enzalutamide
915087-33-1
In house
Anticancer
Commercialized//Validated
Ezetimibe
163222-33-1
USP
Cholesterol Absorption Inhibitor
Commercialized//Validated
Febuxostat
144060-53-7
In house
Antihypercholesterolemic,Antigout
Commercialized//Validated
Ibrutinib
138402-11-6
In house
Antihypertensive
Commercialized//Validated
Irbesartan
936563-96-1
USP/EP
Antiallergic, Anticancer
Commercialized//Validated
Losartan potassium
124750-99-8
USP/EP
Antihypertensive
Commercialized//Validated
Montelukast sodium
151767-02-1
USP/EP
Antiasthma
Commercialized//Validated
Nicorandil
65141-46-0
JP/EP
Anti angina pectoris
Commercialized//Validated
Olmesartan medoxomil
144689-63-4
USP/EP
Antihypertensive
Commercialized//Validated
Oteseconazole
1340593-59-0
In house
Antifungal
Commercialized//Validated
Pregabalin
148553-50-8
In house
Antiepileptic
Commercialized//Validated
Rivaroxaban
366789-02-8
EP
Anticoagulants
Commercialized//Validated
Sacubitril Valsartan Sodium
936623-90-4
In house
Antihypertensive
Commercialized//Validated
Silodosin
160970-54-7
JP/In house
Benign prostatic hyperplasia
Commercialized//Validated
Sitagliptin hydrochloride monohydrate
862156-92-1
In house
Antidiabetic
Commercialized//Validated
Sitagliptin phosphate monohydrate
654671-77-9
USP/EP
Antidiabetic
Commercialized//Validated
Tafluprost
209860-87-7
In house
Antiglaucoma
Commercialized//Validated
Telmisartan
144701-48-4
USP/EP
Antihypertensive
Commercialized//Validated
Ticagrelor
274693-27-5
EP
Antiplatelet
Commercialized//Validated
Valsartan
137862-53-4
USP/EP
Antihypertensive
Commercialized//Validated
Vildagliptin
274901-16-5
In house
Antidiabetic
Commercialized//Validated
Vonoprazan fumarate
881681-01-2
In house
Antiulcer
Commercialized//Validated
Dapagliflozin Free Base
461432-26-8
In house
Antidiabetic
Commercialized//Validated
Relugolix
737789-87-6
In house
Endometriosis
Commercialized//Validated
Finerenone
1050477-31-0
Diabetic nephropathy
Under validation
Bilastine
202189-78-4
Antihistamine
Under validation
Mirogabalin Besylate
1138245-21-2
Analgesic
Under validation
Nebivolol Hydrochloride
152520-56-4
Antihypertensive
Under validation
Abemaciclib
1231929-97-7
Anticancer
Under validation
Vibegron
1190389-15-1
Overactive bladder 
Under validation
Ribociclib Succinate**
1374639-75-4
Anticancer
Under development
Aprocitentan**
1103522-45-7
Antihypertensive
Under development
Elacestrant Dihydrochloride**
1349723-93-8
Anticancer
Under development
Upadacitinib*
2050057-56-0
Antiarthritic
Under development
Acalabrutinib *
1420477-60-6
Anticancer
Under development
Darolutamide*
1297538-32-9
Anticancer
Under development
Alectinib Hydrochloride*
1256589-74-8
Anticancer
Under development
Bempedoic Acid*
CAS(游离碱) 738606-46-7 CAS(盐) N/A
Antilipemic
Under development
Resmetirom*
CAS(游离碱) 920509-32-6
Nonalcoholic Steatohepatitis
Under development
Ruxolitinib Phosphate
CAS(游离碱):941678-49-5 CAS(盐):1092939-17-7
Antimyelofibrosis
Under development
Ritlecitinib Tosilate
2192215-81-7
Antialopecia
Under development
Pirtobrutinib
2101700-15-4
Anticancer
Under development
Ribociclib Succinate
1374639-75-4
Anticancer
Under development

Contact Information

China Sales Center
Tel:+86 (0)576-89189675
Email: tianyu@tianyupharm.com
Latin America Market
Tel:+86 (0)576-89189685
Email:ok@tianyupharm.com
Europe&North America
Market
Tel:+86 (0)576-89189306
Email:hhy@tianyupharm.com
Row Market(CIS、Turkey、Africa、etc.)
Tel:+86 (0)576-89189688
Email:pb@tianyupharm.com
CDMO Service & BD
Tel:+86 (0)21 61917986
Email:cdmo@tianyupharm.com
bd@tianyupharm.com
RESPONSIBILITY
Share Contact Information, Store Details, And
Brand Content With Your Customers.
浙江 © 2024 天宇药业股份有限公司. 浙ICP备09027697号 浙公网安备33100302000925号 由 极简慕枫 Support
Hi! Cookies statement
Tianyu Pharmaceutical attaches great importance to your personal privacy. When you visit our website https://tyyy.mfdemo.cn/ Please agree to use all cookies. If you would like to learn more about how we use cookies, please visit our privacy policy
Accept
Only accept necessary cookies